Systemic inflammatory response during cardiopulmonary bypass and strategies

Journal of Extra-Corporeal Technology

Volumn 37, Issue 2, 2005, Pages 180-188

  Li, Shu ^a,b   Price, Rick ^a   Phiroz, Doc ^a   Swan, Kimberly ^a   Crane, Terry A ^a  

^a TEXAS HEART INSTITUTE   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Cardiopulmonary bypass; Systemic inflammatory response

Indexed keywords

ADRENALIN; ALDOSTERONE; ANGIOTENSIN; ATRIAL NATRIURETIC FACTOR; AUTACOID; BIOMATERIAL; BLOOD CLOTTING FACTOR; BRADYKININ; CALCIUM; COMPLEMENT; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C5A; ENDOTHELIN 1; GLUCAGON; INTERLEUKIN 1; LIOTHYRONINE; LYSOSOME ENZYME; MAGNESIUM; NITRIC OXIDE; NORADRENALIN; OXYGEN RADICAL; POTASSIUM; PROSTAGLANDIN E2; PROTEIN; RENIN; THROMBOCYTE ACTIVATING FACTOR; THYROXINE; VASOACTIVE AGENT; VASOPRESSIN;

ARTICLE; ATELECTASIS; BIOCOMPATIBILITY; BLOOD CLOTTING; CARDIOPULMONARY BYPASS; COMPLEMENT SYSTEM; ENDOTHELIUM CELL; ENDOTOXEMIA; FIBRINOLYSIS; HUMAN; LEUKOCYTE ACTIVATION; LUNG COMPLIANCE; LUNG FUNCTION TEST; LYMPHOCYTE ACTIVATION; MEDIATOR RELEASE; PEROPERATIVE COMPLICATION; PNEUMONIA; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTE ACTIVATION;

EID: 22044454552     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Article

References (104)

1. Edmunds LH. Why cardiopulmonary bypass makes patients sick: strategies to control the blood-synthetic surface interface. Adv in Card Surg. 1995;6:131-67.
2. Pintar T, Collard CD. The systemic inflammatory response to cardiopulmonary bypass. Anesthesiol Clin North America. 2003;21: 453-64.
3. Schulze-Neick I, Li J, Penny DJ, Redington AN. Pulmonary vascular resistance after cardiopulmonary bypass in infants: effect on postoperative recovery. J Thorac Cardiovasc Surg. 2001;121:1033-9.
4. Kotani N, Hashimoto H, Sessler DI, et al. Cardiopulmonary bypass produces greater pulmonary than systemic proinflammatory cytokines. Anesth Analg. 2000;90:1039-45.
5. Ammar T, Silvay O. Factors that influence early extubation: bleeding. J Cardiothorac Vasc Anesth. 1998;12(Suppl 2):28-9.
6. Khabar KS, elBarbary MA, Khouqeer F, Devol E, al-Gain S, al-Halees Z. Circulating endotoxin and cytokines after cardiopulmonary bypass: differential correlation with duration of bypass and systemic inflammatory response/multiple organ dysfunction syndromes. Clin Immunol Immunopathol. 1997;85:97-103.
7. Rothenburger M, Soeparwata R, Deng MC, et al. Prediction of clinical outcome after cardiac surgery: the role of cytokines, endotoxin, and anti-endotoxin core antibodies. Shock. 2001;16(Suppl 1): 44-50.
8. Rothenburger M, Trosch F, Markewitz A, et al. Leukocyte activation and phagocytotic activity in cardiac surgery and infection. Cardiovasc Surg. 2002;10:470-5.
9. Allen ML, Peters MJ, Goldman A, et al. Early postoperative monocyte deactivation predicts systemic inflammation and prolonged stay in pediatric cardiac intensive care. Crit Care Med. 2002;30: 1140-5.
10. Qing M, Vazquez-Jimenez JF, Klosterhalfen B, et al. Influence of temperature during cardiopulmonary bypass on leukocyte activation, cytokine balance, and post-operative organ damage. Shock. 2001;15:372-7.
11. Tamim M, Demircin M, Guvener M, Peker O, Yilmaz M. Heparin-coated circuits reduce complement activation and inflammatory response to cardiopulmonary bypass. Panminerva Med. 1999;41: 193-8.
12. Niimi Y, Ichinose F, Ishiguro Y, et al. The effects of heparin coating of oxygenator fibers on platelet adhesion and protein adsorption. Anesth Analg. 1999;89:573-9.
13. Gunaydin S, Farsak B, Kocakulak M, Sari T, Yorgancioglu C, Zorlutuna Y. Clinical performance and biocompatibility of poly(2-methoxyethylacrylate)-coated extracorporeal circuits. Ann Thorac Surg. 2002;74:819-24.
14. Yung LY, Colman RW, Cooper SL. Neutrophil adhesion on polyurethanes preadsorbed with high molecular weight kininogen. Blood. 1999;94:2716-24.
15. Gallimore MJ, Jones DW, Winter M, Wendel HP. Changes in high molecular weight kininogen levels during and after cardiopulmonary bypass surgery measured using a chromogenic peptide substrate assay. Blood Coagul Fibrinolysis. 2002;13:561-8.
16. Asimakopoulos G. Mechanisms of the systemic inflammatory response. Perfusion. 1999;14:269-77.
17. Gallimore MJ, Jones DW, Wendel HP. A chromogenic substrate assay kit for factor XII: evaluation and use for the measurement of factor XII levels in cardiopulmonary bypass patients. Thromb Res. 1999;94:103-9.
18. Schmaier AH. Contact activation: a revision. Thromb Haemost. 1997;78:101-7.
19. Gil W. Inflammo-coagulatory response, extrinsic pathway thrombin generation and a new theory of activated clotting time interpretation. Perfusion. 2001;16:27-35.
20. Gu YJ, Huyzen RJ, van Oeveren W. Extrinsic pathway-associated activated clotting time for anticoagulation monitoring during cardiopulmonary bypass. Anesth Analg. 1996;83:433.
21. Slaughter TF, LeBleu TH, Douglas JM, Leslie JB, Parker JK. Greenberg CS. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. Anesthesiology. 1994;80:520-6.
22. Chello M, Mastroroberto P, Romano R, Ascione R, Pantaleo D, De Amicis V. Complement and neutrophil activation during cardiopulmonary bypass: a randomized comparison of hypothermic and normothermic circulation. Eur J Cardiothorac Surg. 1997;11:162-8.
23. Royston D. The inflammatory response and extracorporeal circulation. J Cardiothorac Vasc Anesth. 1997;11:341-54.
24. Shastri KA, Logue GL, Stern MP, Rehman S, Raza S. Complement activation by heparin-protamine complexes during cardiopulmonary bypass: effect of C4A null allele. J Thorac Cardiovasc Surg. 1997;114:482-8.
25. Bruins P, te Velthuis H, Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation. 1997;96: 3542-8.
26. Hunt BJ, Parratt RN, Segal HC, Sheikh S, Kallis P, Yacoub M. Activation of coagulation and fibrinolysis during cardiothoracic operations. Ann Thorac Surg. 1998;65:712-8.
27. Miyamoto S, Marcinkiewicz C, Edmunds LH, Niewiarowski S. Measurement of platelet microparticles during cardiopulmonary bypass by means of captured ELISA for GPIIb/IIIa. Thromb Haemost. 1998;80:225-30.
28. Maquelin KN, Berckmans RJ, Nieuwland R, et al. Disappearance of glycoprotein Ib from the platelet surface in pericardial blood during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1998; 115:1160-5.
29. Colman RW. Platelet and neutrophil activation in cardiopulmonary bypass. Ann Thorac Surg. 1990;49:32-4.
30. Ditter H, Heinrich D, Matthias FR, Sellmann-Richter R, Wagner WL, Hehrlein FW. Effects of prostacyclin during cardiopulmonary bypass in men on plasma levels of beta-thromboglobulin, platelet factor 4, thromboxane B2, 6-keto-prostaglandin F1 alpha and heparin. Thromb Res. 1983;32:393-408.
31. George JN, Pickett EB, Saucerman S, et al. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest. 1986;78:340-8.
32. Rinder CS, Mathew JP, Rinder HM, Bonan J, Ault KA, Smith BR. Modulation of platelet surface adhesion receptors during cardiopulmonary bypass. Anesthesiology. 1991;75:563-70.
33. Schlame M, Schmid AB, Haupt R, Rustow B, Kox WJ. Study of platelet-activating factor acetylhydrolase in the perioperative period of patients undergoing cardiac surgery. Shock. 1998;9:313-9.
34. Taggart DP. Biochemical assessment of myocardial injury after cardiac surgery: effects of a platelet activating factor antagonist, bilateral internal thoracic artery grafts, and coronary endarterectomy. J Thorac Cardiovasc Surg. 2000;120:651-9.
35. Boonstra PW, van Imhoff GW, Eysman L, et al. Reduced platelet activation and improved hemostasis after controlled cardiotomy suction during clinical membrane oxygenator perfusions. J Thorac Cardiovasc Surg. 1985;89:900-6.
36. Menasche P. The inflammatory response to cardiopulmonary bypass and its impact on postoperative myocardial function. Curr Opin Cardiol. 1995;10:597-604.
37. Dreyer WJ, Michael LH, Millman EE, Berens KL. Neutrophil activation and adhesion molecule expression in a canine model of open heart surgery with cardiopulmonary bypass. Cardiovasc Res. 1995;29:775-81.
38. Ilton MK, Langton PE, Taylor ML, et al. Differential expression of neutrophil adhesion molecules during coronary artery surgery with cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1999;118: 930-7.
39. Larson DF, Bowers M, Schechner HW. Neutrophil activation during cardiopulmonary bypass in paediatric and adult patients. Perfusion. 1996;11:21-7.
40. Tsuchida M, Watanabe H, Watanabe T, et al. Effect of cardiopulmonary bypass on cytokine release and adhesion molecule expression in alveolar macrophages. Preliminary report in six cases. Am J Respir Crit Care Med. 1997;156:932-8.
41. Chung JH, Gikakis N, Rao AK, Drake TA, Colman RW, Edmunds LH. Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass. Circulation. 1996;93: 2014-8.
42. Verrier ED, Morgan EN. Endothelial response to cardiopulmonary bypass surgery. Ann Thorac Surg. 1998;66:S17-9.
43. Boyle EM, Pohlman TH, Johnson MC, Verrier ED. Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response. Ann Thorac Surg. 1997;63:277-84.
44. Galea J, Rebuck N, Finn A, Manche A, Moat N. Expression of soluble endothelial adhesion molecules in clinical cardiopulmonary bypass. Perfusion. 1998;13:314-21.
45. Boldt J, Osmer C, Linke LC, Dapper F, Hempelmann G. Circulating adhesion molecules in pediatric cardiac surgery. Anesth Analg. 1995;81:1129-35.
46. Elliott MJ, Finn AH. Interaction between neutrophils and endothelium. Ann Thorac Surg. 1993;56:1503-8.
47. Boyle EM, Verrier ED, Spiess BD. Endothelial cell injury in cardiovascular surgery: the procoagulant response. Ann Thorac Surg. 1996;62:1549-57.
48. Korthuis RJ, Anderson DC, Granger DN. Role of neutrophil-endothelial cell adhesion in inflammatory disorders. J Crit Care. 1994;9:47-71.
49. Habermehl P, Knuf M, Kampmann C, et al. Changes in lymphocyte subsets after cardiac surgery in children. Eur J Pediatr. 2003;162: 15-21.
50. Perttila J, Salo M, Pirttikangas CO, Jalonen J, Vainio O. Effects of cardiopulmonary bypass on lymphocytes and their subset counts with or without use of autotransfusion devices. J Cardiothorac Vasc Anesth. 1994;8:532-5.
51. Martinez-Pellus AE, Merino P, Bru M, et al. Endogenous endotoxemia of intestinal origin during cardiopulmonary bypass. Role of type of flow and protective effect of selective digestive decontamination. Intensive Care Med. 1997;23:1251-7.
52. Gercekoglu H, Tarim O, Agar I, et al. Effects of hypothermia on blood endogenous endotoxin levels during cardiopulmonary bypass. J Cardiol Surg. 1997;12:223-7.
53. Schneider M, Valentine S, Hegde RM, Peacock J, March S, Dobb GJ. The effect of different bypass flow rates and low-dose dopamine on gut mucosal perfusion and outcome in cardiac surgical patients. Anaesth Intensive Care. 1999;27:13-9.
54. Kharazmi A, Andersen LW, Baek L, Valerius NH, Laub M, Rasmussen JP. Endotoxemia and enhanced generation of oxygen radicals by neutrophils from patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1989;98:381-5.
55. Asimakopoulos G, Smith PL, Ratnatunga CP, Taylor KM. Lung injury and acute respiratory distress syndrome after cardiopulmonary bypass. Ann Thorac Surg. 1999;68:1107-15.
56. Despotis GJ, Goodnough LT. Management approaches to platelet-related microvascular bleeding in cardiothoracic surgery. Ann Thorac Surg. 2000;70(2 Suppl):S20-32.
57. Massoudy P, Zahler S, Becker BF, Braun SL, Barankay A, Meisner H. Evidence for inflammatory responses of the lungs during coronary artery bypass grafting with cardiopulmonary bypass. Chest. 2001;119:31-6.
58. Wei M, Kuukasjarvi P, Laurikka J, et al. Soluble adhesion molecules and myocardial injury during coronary artery bypass grafting. World J Surg. 2003;27:140-4.
59. Grunenfelder J, Zund G, Schoeberlein A, et al. Expression of adhesion molecules and cytokines after coronary artery bypass grafting during normothermic and hypothermie cardiac arrest. Eur J Cardiothorac Surg. 2000;17:723-8.
60. Rady MY, Ryan T, Starr NJ. Early onset of acute pulmonary dysfunction after cardiovascular surgery: risk factors and clinical outcome. Crit Care Med. 1997;25:1831-9.
61. Cox CM, Ascione R, Cohen AM, Davies IM, Ryder IG, Angelini GD. Effect of cardiopulmonary bypass on pulmonary gas exchange: a prospective randomized study. Ann Thorac Surg. 2000;69:140-5.
62. Gillinov AM, Redmond JM, Zehr KJ, et al. Inhibition of neutrophil adhesion during cardiopulmonary bypass. Ann Thorac Surg. 1994; 57:126-33.
63. Fung M, Loubser PG, Undar A, et al. Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits. J Thorac Cardiovasc Surg. 2001;122:113-22.
64. Gupta-Bansal R, Parent JB, Brunden KR. Inhibition of complement alternative pathway function with anti-properdin monoclonal antibodies. Mol Immunol. 2000;37:191-201.
65. Gorman JH, Edmunds LH. Blood anesthesia for cardiopulmonary bypass. J Card Surg. 1995;10:270-9.
66. Rubens FD, Mesana T. The inflammatory response to cardiopulmonary bypass: a therapeutic overview. Perfusion. 2004;19:S5-12.
67. Gorman RC, Ziats N, Rao AK, et al. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1996;111:1-11.
68. Fosse E, Thelin S, Svennevig JL, et al. Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect the release of granulocyte enzymes: a European multicentre study. Eur J Cardiothorac Surg. 1997;11:320-7.
69. Defraigne JO, Pincemail J, Larbuisson R, Blaffart F, Limet R. Cytokine release and neutrophil activation are not prevented by heparin-coated circuits and aprotinin administration. Ann Thorac Surg. 2000;69:1084-91.
70. Butler J, Murithi EW, Pathi VL, MacArthur KJ, Berg GA. Duroflo II heparin bonding does not attenuate cytokine release or improve pulmonary function. Ann Thorac Surg. 2002;74:139-42.
71. Matheve C. Clinical evidence of improved biocompatibility using heparin-coated surfaces. Perfusion. 1996;11:264-9.
72. Hsu LC. Biocompatibility in cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 1997;11:376-82.
73. Gourlay T. Biomaterial development for cardiopulmonary bypass. Perfusion. 2001;16:381-90.
74. Vocelka C, Lindley G. Improving cardiopulmonary bypass: heparin-coated circuits. J Extra Corpor Technol. 2003;35:312-6.
75. Borowiec J, Bagge L, Saldeen T, Thelin S. Biocompatibility reflected by haemostasis variables during cardiopulmonary bypass using heparin-coated circuits. Thorac Cardiovasc Surg. 1997; 45:163-7.
76. Lilly KJ, O'Gara PJ, Treanor PR, et al. Cardiopulmonary bypass: it's not the size, it's how you use it! Review of a comprehensive blood-conservation strategy. J Extra Corpor Technol. 2004;36: 263-8.
77. Feddersen K, Aurell M, Delin K, Haggendal J, Aren C, Radegran K. Effects of cardiopulmonary bypass and prostacyclin on plasma catecholamines, angiotensin II and arginine-vasopressin. Acta Anaesthesiol Scand. 1985;29:224-30.
78. Sly MK, Prager MD, Eberhart RC, Jessen ME, Kulkarni PV. Inhibition of surface-induced platelet activation by nitric oxide. ASAIO J. 1995;41:M394-8.
79. Suzuki Y, Malekan R, Hanson CW, et al. Platelet anesthesia with nitric oxide with or without eptifibatide during cardiopulmonary bypass in baboons. J Thorac Cardiovasc Surg. 1999;117:987-93.
80. Boldt J, Knothe C, Zickmann B, Wege N, Dapper F, Hempelmann G. Aprotinin in pediatric cardiac operations: platelet function, blood loss, and use of homologous blood. Ann Thorac Surg. 1993; 55:1460-6.
81. Shinfeld A, Zippel D, Lavee J, et al. Aprotinin improves hemostasis after cardiopulmonary bypass better than single-donor platelet concentrate. Ann Thorac Surg. 1995;59:872-6.
82. Primack C, Walenga JM, Koza MJ, Shankey TV, Pifarre R. Aprotinin modulation of platelet activation in patients undergoing cardiopulmonary bypass operations. Ann Thorac Surg. 1996;61:1188-93.
83. Landis RC, Haskard DO, Taylor KM. New antiinflammalory and platelet-preserving effects of aprotinin. Ann Thorac Surg. 2001;72: S1808-13.
84. Chello M, Mastroroberto P, Marchese AR, Maltese G, Santangelo E, Amantea B. Nitric oxide inhibits neutrophil adhesion during experimental extracorporeal circulation. Anesthesiology. 1998;89: 443-8.
85. Sato Y, Hiramatsu Y, Homma S, Sato S, Onizuka M, Sakakibara Y. Phosphodiesterase type 4 inhibition of activated polymorphonuclear leukocytes in a simulated extracorporeal circulation model. J Thorac Cardiovasc Surg. 2003;125:172-7.
86. Ustunsoy H, Sivrikoz MC, Bakir K, et al. The inhibition of pro-inflammatory cytokines with pentoxifylline in the cardiopulmunary bypass lung. Respir Med. 2002;96:275-9.
87. Fansa I, Gol M, Nisanoglu V, Yavas S, Iscan Z, Tasdemir O. Does diltiazem inhibit the inflammatory response in cardiopulmonary bypass? Med Sci Monit. 2003;9:PI30-6.
88. Bronicki RA, Backer CL, Baden HP, Mavroudis C, Crawford SE, Green TP. Dexamethasone reduces the inflammatory response to cardiopulmonary bypass in children. Ann Thorac Surg. 2000;69: 1490-5.
89. Kawamura T, Inada K, Okada H, Okada K, Wakusawa R. Methylprednisolone inhibits increase of interleukin 8 and 6 during open heart surgery. Can J Anaesth. 1995;42:399-403.
90. Jansen NJ, van Oeveren W, van den Broek L, et al. Inhibition by dexamethasone of the reperfusion phenomena in cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1991;102:515-25.
91. Prasad K, Chan WP, Bharadwaj B. Superoxide dismutase and catalase in protection of cardiopulmonary bypass-induced cardiac dysfunction and cellular injury. Can J Cardiol. 1996;12:1083-91.
92. Tanita T, Song C, Kubo H, et al. Superoxide anion mediates pulmonary vascular permeability caused by neutrophils in cardiopulmonary bypass. Surg Today. 1999;29:755-61.
93. Vertrees RA, Tao W, Kramer GC, et al. Tumor necrosis factor monoclonal antibody prevents alterations in leukocyte populations during cardiopulmonary bypass. ASAIO J. 1994;40:M554-9.
94. Hayashi Y, Sawa Y, Nishimura M, et al. P-selectin monoclonal antibody may attenuate the whole body inflammatory response induced by cardiopulmonary bypass. ASAIO J. 2000;46:334-7.
95. Ashraf S, Butler J, Tian Y, et al. Inflammatory mediators in adults undergoing cardiopulmonary bypass: comparison of centrifugal and roller pumps. Ann Thorac Surg. 1998;65:480-4.
96. Lindholm L, Westerberg M, Bengtsson A, Ekroth R, Jensen E, Jeppsson A. A closed perfusion system with heparin coating and centrifugal pump improves cardiopulmonary bypass biocompatibility in elderly patients. Ann Thorac Surg. 2004;78:2131-8.
97. Millar AB, Armstrong L, van der Linden J, et al. Cytokine production and hemofiltration in children undergoing cardiopulmonary bypass. Ann Thorac Surg. 1993;56:1499-502.
98. Darling E, Searles B, Nasrallah F, et al. High-volume, zero balanced ultrafiltration improves pulmonary function in a model of post-pump syndrome. J Extra Corpor Technol. 2002;34:254-9.
99. Fitzgerald DJ, Cecere G. Hemofiltration and inflammatory mediators. Perfusion. 2002;17S:23-8.
100. Aldea GS, Soltow LO, Chandler WL, et al. Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits. J Thorac Cardiovasc Surg. 2002;123:742-55.
101. Westerberg M, Bengtsson A, Jeppsson A. Coronary surgery without cardiotomy suction and autotransfusion reduces the post-operative systemic inflammatory response. Ann Thorac Surg. 2004; 78:54-9.
102. Gu YJ, de Vries AJ, Boonstra PW, van Oeveren W. Leukocyte depletion results in improved lung function and reduced inflammatory response after cardiac surgery. J Thorac Cardiovasc Surg. 1996; 112:494-500.
103. Treacher DF, Sabbato M, Brown KA, Gant V. The effects of leucodepletion in patients who develop the systemic inflammatory response syndrome following cardiopulmonary bypass. Perfusion. 2001;16S:67-73.
104. Asimakopoulos G. The inflammatory response to CPB: the role of leukocyte filtration. Perfusion. 2002;17:7-10.